Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529–42.

Article  PubMed  Google Scholar 

Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–52.

Article  CAS  PubMed  Google Scholar 

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.

Article  PubMed  PubMed Central  Google Scholar 

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.

Article  PubMed  PubMed Central  Google Scholar 

Ameisen JC. On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ. 2002;9(4):367–93.

Article  CAS  PubMed  Google Scholar 

Loftus LV, Amend SR, Pienta KJ. Interplay between cell death and cell proliferation reveals new strategies for cancer therapy. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23094723.

Article  PubMed  PubMed Central  Google Scholar 

Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol. 2020;38:567–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuriakose T, Man SM, Malireddi RK, Karki R, Kesavardhana S, Place DE, et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Science immunology. 2016;1(2).

Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021;19:4641–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yi X, Li J, Zheng X, Xu H, Liao D, Zhang T, et al. Construction of PANoptosis signature: novel target discovery for prostate cancer immunotherapy. Mol Ther Nucleic Acids. 2023;33:376–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan H, Pan J, Li P, Gao J. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer. Clin Immunol. 2022;238: 109019.

Article  CAS  PubMed  Google Scholar 

Ajibade AA, Wang HY, Wang RF. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013;34(7):307–16.

Article  CAS  PubMed  Google Scholar 

Malireddi RKS, Karki R, Sundaram B, Kancharana B, Lee S, Samir P, et al. Inflammatory cell death, PANoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth. ImmunoHorizons. 2021;5(7):568–80.

Article  PubMed  Google Scholar 

Wilkerson MD, Hayes DN. Consensusclusterplus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Z, Xu J, Fan Y, Qi Y, Wang S, Zhao S, et al. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. J Exper Clinic Cancer Res: CR. 2022;41(1):223.

Article  CAS  Google Scholar 

Li Y, Liu H, Yan H, Xiong J. Research advances on targeted-Treg therapies on immune-mediated kidney diseases. Autoimmun Rev. 2023;22(2): 103257.

Article  CAS  PubMed  Google Scholar 

Wang X, Lopez R, Luchtel RA, Hafizi S, Gartrell B, Shenoy N. Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int. 2021;99(1):75–85.

Article  CAS  PubMed  Google Scholar 

Drake CG, Stein MN. The immunobiology of kidney cancer. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.79.2648.

Article  PubMed  Google Scholar 

Lucarelli G, Lasorsa F, Milella M, d'Amati A, Ingravallo G, Silecchia M, et al. Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma. Urologic oncology. 2025.

di Meo NA, Lasorsa F, Rutigliano M, Milella M, Ferro M, Battaglia M, et al. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Rev Mol Diagn. 2023;23(4):297–13.

Article  PubMed  Google Scholar 

Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–07.

Article  CAS  PubMed  Google Scholar 

di Meo NA, Lasorsa F, Rutigliano M, Loizzo D, Ferro M, Stella A, et al. Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232214360.

Article  PubMed  PubMed Central  Google Scholar 

De Marco S, Torsello B, Minutiello E, Morabito I, Grasselli C, Bombelli S, et al. The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell renal cell carcinoma cells. FEBS Lett. 2023;597(8):1098–113.

Article  PubMed  Google Scholar 

Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–15.

Article  PubMed  PubMed Central  Google Scholar 

Ragone R, Sallustio F, Piccinonna S, Rutigliano M, Vanessa G, Palazzo S, et al. Renal cell carcinoma: a study through NMR-based metabolomics combined with transcriptomics. Diseases. 2016. https://doi.org/10.3390/diseases4010007.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli G, Galleggiante V, Rutigliano M, Sanguedolce F, Cagiano S, Bufo P, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371–86.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli G, Rutigliano M, Sallustio F, Ribatti D, Giglio A, Lepore Signorile M, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging. 2018;10(12):3957–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bombelli S, Torsello B, De Marco S, Lucarelli G, Cifola I, Grasselli C, et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am J Pathol. 2020;190(11):2317–26.

Article  CAS  PubMed  Google Scholar 

Lucarelli G, Rutigliano M, Loizzo D, di Meo NA, Lasorsa F, Mastropasqua M, et al. MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232213968.

Article  PubMed  PubMed Central  Google Scholar 

Milella M, Rutigliano M, Lasorsa F, Ferro M, Bianchi R, Fallara G, et al. The role of MUC1 in renal cell carcinoma. Biomolecules. 2024. https://doi.org/10.3390/biom14030315.

Article  PubMed  PubMed Central  Google Scholar